GGrantIndex
← Leaderboards

Beatrice A Golomb

University Of California San Diego

$6,262,264
Attributed
$6,262,264
Total exposure
10
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $237K · FY200525
$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,262,264 · 10

By mechanism

R01$4,834,820 · 1
M01$857,388 · 7
R21$434,500 · 1
R34$135,556 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of California San Diego

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchUnited States National Institutes Of HealthCoenzyme Q10Research PersonnelResourcesSourceGrantFundingAggressionHuman SubjectSerotoninPsychomotor FunctionAntihypercholesterolemic AgentQuality Of LifeBehavioral /Social Science Research TagInstitutionHuman Therapy EvaluationDrug Adverse EffectComputer Retrieval Of Information On Scientific Projects DatabaseFutureBlood ChemistryModificationCognitionReporting

Grant awards (23)

Uncovering the Short-Term Public Health Impact of Toxin Release in East Palestine, Ohio: Outcomes and Effect Modifiers$197,500
R21 · FY2025 · ES · contact PI
Uncovering the Short-Term Public Health Impact of Toxin Release in East Palestine, Ohio: Outcomes and Effect Modifiers$237,000
R21 · FY2024 · ES · contact PI
Q10 AND GULF WAR VETERANS$30,375
M01 · FY2010 · RR · contact PI
COENZYME Q10 IN AGING: A PILOT STUDY$8,112
M01 · FY2010 · RR · contact PI
COENZYME Q10 IN AGING: A PILOT STUDY$86,626
M01 · FY2009 · RR · contact PI
Q10 AND GULF WAR VETERANS$12,455
M01 · FY2009 · RR · contact PI
COENZYME Q10 IN AGING: A PILOT STUDY$457
M01 · FY2008 · RR · contact PI
Coenzyme Q10 in Aging: A Planning Grant$135,556
R34 · FY2005 · AG
STATINS AND NON-CARDIOVASCULAR ENDPOINTS$36,632
M01 · FY2005 · RR
Statins and Non-Cardiovascular Endpoints$682,731
M01 · FY2004 · RR
STATINS AND NON-CARDIAC ENDPOINTS$489,480
R01 · FY2003 · HL
STATINS AND NON-CARDIAC ENDPOINTS$1,237,020
R01 · FY2002 · HL
STATINS AND NONCARDIOVASCULAR ENDPOINTS$0
M01 · FY2002 · RR
STATINS AND NONCARDIOVASCULAR ENDPOINTS$0
M01 · FY2002 · RR
STATINS AND NONCARDIOVASCULAR ENDPOINTS$0
M01 · FY2002 · RR
STATINS AND NONCARDIOVASCULAR ENDPOINTS$0
M01 · FY2002 · RR
STATINS AND NON-CARDIAC ENDPOINTS$1,788,590
R01 · FY2001 · HL
STATINS AND NONCARDIOVASCULAR ENDPOINTS$0
M01 · FY2001 · RR
STATINS AND NONCARDIOVASCULAR ENDPOINTS$0
M01 · FY2001 · RR
STATINS AND NON-CARDIAC ENDPOINTS$1,319,730
R01 · FY2000 · HL
STATINS AND NONCARDIOVASCULAR ENDPOINTS$0
M01 · FY2000 · RR
STATINS AND NONCARDIOVASCULAR ENDPOINTS$0
M01 · FY2000 · RR
STATINS AND NONCARDIOVASCULAR ENDPOINTS$0
M01 · FY2000 · RR